<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01916278</url>
  </required_header>
  <id_info>
    <org_study_id>05DF1215</org_study_id>
    <nct_id>NCT01916278</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Lip Injections With Emervel Lips Lidocaine and Juvéderm Volbella With Lidocaine</brief_title>
  <official_title>A Randomized, Evaluator-blinded, Comparative Study of the Safety and Efficacy of Lip Injections With Emervel Lips Lidocaine and Juvéderm Volbella With Lidocaine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 12-month, randomised, evaluator-blinded, comparative, multicentre study of the safety and&#xD;
      efficacy of lip injections with Emervel Lips Lidocaine and Juvéderm Volbella with Lidocaine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Lip Fullness Grading Scale (LFGS) score</measure>
    <time_frame>0-12 months</time_frame>
    <description>To evaluate esthetic change of lips from baseline using LFGS</description>
  </primary_outcome>
  <other_outcome>
    <measure>Global Aesthetic Improvement Scale (GAIS)score</measure>
    <time_frame>1-12 months</time_frame>
    <description>To evaluate esthetic change of lips from baseline using GAIS</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's satisfaction</measure>
    <time_frame>0-12 months</time_frame>
    <description>To evaluate subject's satisfaction in terms of a subject satisfaction questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Investigator's assessment of treatment procedure</measure>
    <time_frame>0-2 weeks</time_frame>
    <description>To evaluate the ease of injection and moulding</description>
  </other_outcome>
  <other_outcome>
    <measure>Local tolerability</measure>
    <time_frame>14 days</time_frame>
    <description>To assess local tolerability after treatment including bruising, redness, swelling, pain, tenderness and itching at 14 days. Local tolerability ongoing 2 weeks after treatment will be recorded as an AE and continued follow-up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's assessment of treatment pain</measure>
    <time_frame>0-2 weeks</time_frame>
    <description>To evaluate subject's experience of pain during treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Product palpability</measure>
    <time_frame>0-2 weeks</time_frame>
    <description>To evaluate if study product is palpable or not palpable. If assessed as palpable, also to evaluate if the feel is expected/normal or unexpected/abnormal. Unexpected feel of palpable product present 2 weeks after treatment will be recorded as an AE and continued follow-up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Event reporting</measure>
    <time_frame>0-12 months</time_frame>
    <description>To evaluate long-term safety throughout the study period</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Lip Filler Injections</condition>
  <arm_group>
    <arm_group_label>Emervel Lips Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Juvéderm Volbella with Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Emervel Lips Lidocaine</intervention_name>
    <arm_group_label>Emervel Lips Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Juvéderma Volbella with Lidocaine</intervention_name>
    <arm_group_label>Juvéderm Volbella with Lidocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female and male subjects aged 18 to 65 years.&#xD;
&#xD;
          -  Subjects with the intention to undergo lip augmentation treatment (vermilion mucosa&#xD;
             and, if applicable, vermilion borders).&#xD;
&#xD;
          -  Subjects with LFGS score of 0 (very thin), 1 (thin) and 2 (moderately thick) (scores&#xD;
             may differ between upper and lower lip), and lip appearance judged by the treating&#xD;
             investigator to be suitable for optimal correction (≥ 1 grade improvement on the LFGS&#xD;
             per lip) with maximum 1.5 mL study product per lip.&#xD;
&#xD;
          -  Subjects with signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant anticoagulant therapy and therapy with inhibitors of platelet aggregation&#xD;
             (e.g. aspirin or other nonsteroidal anti-inflammatory drugs [NSAIDs]), Omega-3 or&#xD;
             vitamin E within 10 days before study treatment, or a history of bleeding disorders.&#xD;
&#xD;
          -  Prior surgery or tattoo to the upper or lower lip or lip line.&#xD;
&#xD;
          -  Presence of any abnormal lip structure, such as a scar or lump or severe lip&#xD;
             asymmetry, as judged by the investigator. Tendency to form keloids, hypertrophic scars&#xD;
             or any other healing disorders.&#xD;
&#xD;
          -  Previous tissue augmenting therapy in the lip area (including lips, oral commissures,&#xD;
             nasolabial folds, marionette and perioral lines) with HA or collagen filler, or laser&#xD;
             treatment, within 12 months before study entry.&#xD;
&#xD;
          -  Permanent implant or treatment with non-HA or non-collagen filler in the lip area&#xD;
             (including lips, oral commissures, nasolabial folds, marionette and perioral lines).&#xD;
&#xD;
          -  Previous toxin treatment below the lower orbital rim within 9 months before study&#xD;
             entry.&#xD;
&#xD;
          -  History of herpes labialis with an outbreak within 4 weeks of study entry or with 4 or&#xD;
             more outbreaks in the 12 months before study entry.&#xD;
&#xD;
          -  Active skin disease, inflammation or related conditions, such as infection, psoriasis&#xD;
             and herpes zoster near or on the area to be treated.&#xD;
&#xD;
          -  History of angioedema.&#xD;
&#xD;
          -  Known hypersensitivity to HA, lidocaine or other amide-type anaesthetics or history of&#xD;
             severe multiple allergies or anaphylactic shock&#xD;
&#xD;
          -  Cancerous or precancerous lesions in the area to be treated.&#xD;
&#xD;
          -  Immunosuppressive therapy, chemotherapy, treatment with biologics or systemic&#xD;
             corticosteroids within 3 months before study treatment.&#xD;
&#xD;
          -  Any medical condition that in the opinion of the investigator would make the subject&#xD;
             unsuitable for inclusion (e.g. a chronic, relapsing or hereditary disease that may&#xD;
             affect the general condition or may require frequent medical treatment).&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Participation in any other clinical study within 30 days before inclusion.&#xD;
&#xD;
          -  Other condition preventing the subject to entering the study in the investigator's&#xD;
             opinion, e.g. subjects not likely to avoid other facial cosmetic treatments below the&#xD;
             level of the lower orbital rim and chin, subjects anticipated to be unreliable or&#xD;
             incapable of understanding and complying with the study assessment or unrealistic&#xD;
             expectations of treatment result.&#xD;
&#xD;
          -  Study site staff or close relatives to study site staff and employees at the sponsor&#xD;
             company or close relatives to employees at the sponsor company. Close relatives are&#xD;
             defined as parents, children, siblings and spouse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rosenpark Research</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Skin Center</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademikliniken</name>
      <address>
        <city>Stockholm</city>
        <zip>115 42</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>July 18, 2013</study_first_submitted>
  <study_first_submitted_qc>August 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2013</study_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

